Dr. Annalisa Jenkins is a life sciences thought leader with over 20 years of biopharmaceutical industry experience. Prior to joining PlaqueTec as CEO in November 2017, Dr. Jenkins served as president and CEO of Dimension Therapeutics, a leading gene therapy company that was acquired by Ultragenyx in November 2017. Prior leadership roles have included the head of global research and development and executive vice president global development and medical at Merck Serono, and several senior positions at Bristol Myers-Squibb over 15 years - including serving as senior vice president and head of global medical affairs. Earlier in her career, Dr. Jenkins was a medical officer in the British Royal Navy during the Gulf Conflict, achieving the rank of surgeon lieutenant commander. Dr. Jenkins is a board member of several growing companies, including Ardelyx, Inc., iOX Therapeutics Limited, Thrombolytic Strategies Incorporated, PhESi, Oncimmune, Cocoon Biotech Inc. (Non Executive Chair), Cellmedica (Non-Executive Chair), Vium, Inc. (Executive Chair), and Silence Therapeutics (Non-Executive Chair). She also is a committee member of the Science Board to the U.S. Food & Drug Administration (FDA), and serves on the board of the Center for Talent Innovation in the U.K. Dr. Jenkins graduated with a degree in medicine from St. Bartholomew’s Hospital in the University of London and subsequently trained in cardiovascular medicine in the U.K. National Health Service.

Bob Damms MA (Cantab) is an expert in the assessment and development of new products and technologies. He has over 25 years' experience of developing new biomedical technologies through roles in industry, consulting, venture capital and equities research. He has worked across most biomedical subsectors, including biotechnology, pharmaceuticals, medical devices and eHealth, and from university start-ups, SMEs, global corporations and governments. His particular interests include the convergence of technologies in the healthcare sector, translational research, and novel commercialisation models. He is currently seconded to the UKTI's Venture Capital unit.

Carl Brookes DM FRCP trained at Oxford University and St Thomas' Hospital, London.  He has been a Consultant Physician and Cardiologist at Hampshire Hospitals Foundation Trust since 2000. He runs a comprehensive invasive and non-invasive cardiology service and is also the Divisional Medical Director for Medical Services overseeing 1500 staff with a budget of £80m. He has widespread research interests across cardiology and internal medicine including diabetes mellitus.

Scott Greenhalgh is a former director of Samuel Montegu, partner of Alchemy private equity and managing director of Vision Capital. He now chairs a number of companies and sits on the board of others both in Germany and the UK. His not-for-profit work includes being a member of the England Committee of the BIG Lottery Fund and a Trustee of Pilotlight.